CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 70% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.9689
7.3%
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.0322
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024929 %
Charges from full value of position ($-4.74)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024929%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002707 %
Charges from full value of position ($0.51)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002707%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 3.6989
Open 3.6889
1-Year Change -76.86%
Day's Range 3.6889 - 4.0389
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 4, 2024 3.9689 0.2800 7.59% 3.6889 4.0589 3.6489
Nov 1, 2024 3.6989 0.2300 6.63% 3.4689 3.7689 3.4689
Oct 31, 2024 3.5289 -0.2400 -6.37% 3.7689 3.7889 3.5289
Oct 30, 2024 3.7689 -0.3500 -8.50% 4.1189 4.1889 3.7489
Oct 29, 2024 4.1789 0.1400 3.47% 4.0389 4.2089 3.9889
Oct 28, 2024 4.0789 0.1400 3.55% 3.9389 4.2489 3.8989
Oct 25, 2024 3.8989 0.0500 1.30% 3.8489 4.0089 3.8389
Oct 24, 2024 3.8389 -0.2000 -4.95% 4.0389 4.0889 3.8189
Oct 23, 2024 4.0189 -0.1800 -4.29% 4.1989 4.3089 3.9589
Oct 22, 2024 4.2689 -0.1400 -3.18% 4.4089 4.5589 4.2189
Oct 21, 2024 4.4989 -0.3000 -6.25% 4.7989 4.8889 4.2689
Oct 18, 2024 4.8889 0.0300 0.62% 4.8589 4.9189 4.6589
Oct 17, 2024 4.8389 0.2100 4.54% 4.6289 4.8589 4.5289
Oct 16, 2024 4.6589 0.3300 7.62% 4.3289 4.6689 4.1989
Oct 15, 2024 4.3089 0.0700 1.65% 4.2389 4.3689 4.1589
Oct 14, 2024 4.2389 0.1400 3.42% 4.0989 4.3489 4.0889
Oct 11, 2024 4.1889 0.3000 7.71% 3.8889 4.2889 3.8389
Oct 10, 2024 3.9389 -0.2300 -5.52% 4.1689 4.1689 3.8189
Oct 9, 2024 4.1189 -0.0600 -1.44% 4.1789 4.2889 4.0289
Oct 8, 2024 4.3089 0.3100 7.75% 3.9989 4.4289 3.9589

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cabaletta Bio, Inc. Company profile

About Cabaletta Bio Inc

Cabaletta Bio Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company's lead CAAR T cell product candidate is designed based on chimeric antigen receptor (CAR), and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cabaletta Bio Inc revenues was not reported. Net loss increased 39% to $46.3M. Higher net loss reflects Research and development increase of 53% to $29.7M (expense), Stock-based Compensation in R&D increase of 38% to $2.7M (expense), General and administrative increase of 7% to $10.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.44 to -$1.80.

Industry: Bio Therapeutic Drugs

2929 Arch Street
Suite 600
PHILADELPHIA
PENNSYLVANIA 19104
US

News

RBA meeting preview: No change to policy expected as inflation fight continues

The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.

13:35, 4 November 2024

US elections: Trump leads the polls, but tariff talk spooks investors

As the US elections get closer we look at how Trump’s tariff plans could affect markets.

15:02, 22 October 2024

Gold markets to trade

Last week, we explored the basic fundamental and technical approaches to gold trading. Having covered the key price drivers of this critical asset and how you might use data to trade it, you’re ready to assess the conditions for entry. But there are a range of markets that can effectively give you exposure to gold.

08:00, 21 October 2024

US earnings seasons off to a solid start as focus shifts to tech giants

The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.

14:31, 17 October 2024

ECB Preview: cooling growth and inflation call for another rate cut

Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.

12:41, 16 October 2024

Australian labour force data forecast to reveal stable jobs market

Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.

07:41, 15 October 2024

Applying fundamental and technical strategies to Gold Trading

Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.

08:00, 14 October 2024

People also watch

US100

20,046.10 Price
+0.270% 1D Chg, %
Long position overnight fee -0.0249%
Short position overnight fee 0.0027%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,742.12 Price
+0.220% 1D Chg, %
Long position overnight fee -0.0180%
Short position overnight fee 0.0098%
Overnight fee time 22:00 (UTC)
Spread 0.30

Oil - Crude

71.46 Price
-0.070% 1D Chg, %
Long position overnight fee 0.0101%
Short position overnight fee -0.0320%
Overnight fee time 22:00 (UTC)
Spread 0.040

BTC/USD

68,862.80 Price
+2.530% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading